Seven Eight Capital LP Takes $686,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Seven Eight Capital LP purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 6,432 shares of the specialty pharmaceutical company’s stock, valued at approximately $686,000.

A number of other large investors also recently bought and sold shares of the business. Rise Advisors LLC grew its holdings in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. Versant Capital Management Inc grew its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the last quarter. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares in the last quarter. Cape Investment Advisory Inc. raised its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares during the last quarter. Finally, Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals in the second quarter worth $33,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $110.76 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.38. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of 22.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a 50 day moving average of $110.79 and a 200 day moving average of $111.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. On average, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the subject of several analyst reports. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Royal Bank of Canada cut their price target on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.